RETRACTED: Baseline plasma N-terminal pro-B-type natriuretic peptide is associated with the extent of stress-induced myocardial ischernia during dobutamine stress echocardiography (Retracted Article)

被引:7
作者
Feringa, Harm H. H.
Elhendy, Abdou
Bax, Jeroen J.
Boersma, Eric
de Jonge, Robert
Schouten, Olaf
Karagiannis, Stefanos E.
Schinkel, Arend F. L.
Lindemans, Jan
Poldermans, Don
机构
[1] Erasmus MC, Dept Anesthesiol, Rotterdam, Netherlands
[2] Erasmus MC, Dept Cardiol, Rotterdam, Netherlands
[3] Erasmus MC, Dept Clin Chem, Rotterdam, Netherlands
[4] Erasmus MC, Dept Vasc Surg, Rotterdam, Netherlands
[5] Leiden Univ, Dept Cardiol, Med Ctr, Leiden, Netherlands
[6] Univ Nebraska, Dept Internal Med, Cardiol Sect, Omaha, NE 68182 USA
[7] Onassis Cardiac Surg Ctr, Dept Cardiol, Athens, Greece
关键词
dobutamine stress echocardiography; myocardial ischemia; natriuretic peptides; predictive value;
D O I
10.1097/00019501-200605000-00009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To determine the relationship between baseline plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and the presence and extent of myocardial ischemia during dobutamine stress echocardiography (DSE), ischernic segments, respectively (P < 0.001). Elevated NT-proBNP levels were significantly associated with NWMAs (odds ratio per 100 ng/l increase: 1.14, 95% confidence interval: 1.1-1.2) in a multivariate analysis of clinical baseline variables and RWMAs. Methods NT-proBNP was measured in 170 consecutive patients prior to DSE. Rest wall motion abnormalities (RWMAs) and new wall motion abnormalities (NWMAs) were scored using a 5-point, 17-segment model. Kruskal-Wallis tests were applied to study differences in NT-proBNP levels between patients with normal DSE, RWMAs but no NWMAs, and NWMAs, and (in patients with NWMAs) between those with 1-2, 3-4 and > 4 ischernic segments. Univariate and multivariate regression analyses were used to determine the value of NT-proBNP in predicting NWMAs. Results The median NT-proBNP level was 110ng/l (interquartile range: 42-389 ng/1). Median NT-proBNP was 59, 321 and 440 ng/l in patients with normal DSE, with RWMAs but no NWMAs, and with NWMAs, respectively (P < 0001). Among patients with NWMAs, median NT-proBNP was associated with the number of ischernic segments: 364, 710 and 2376 ng/l in patients with 1-2, 3-4 and > 4 ischemic segments, respectively (P < 0.001). Elevated NT-proBNP levels were significantly associated with NWMAs (odds ratio per 100 ng/l increase: 1.14, 95% confidence interval: 1.1-1.2) in a multivariate analysis of clinical baseline variables and RWMAs. Conclusion Elevated baseline levels of NT-proBNP are associated with the presence and extent of myocardial ischemia during DSE, independent of the presence of RWMAs.
引用
收藏
页码:255 / 259
页数:5
相关论文
共 19 条
[1]   N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients [J].
Bettencourt, P ;
Azevedo, A ;
Pimenta, J ;
Frioes, F ;
Ferreira, S ;
Ferreira, A .
CIRCULATION, 2004, 110 (15) :2168-2174
[2]   The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes [J].
de Lemos, JA ;
Morrow, DA ;
Bentley, JH ;
Omland, T ;
Sabatine, MS ;
McCabe, CH ;
Hall, C ;
Cannon, CP ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (14) :1014-1021
[3]   N-terminal pro-brain natriuretic peptide -: A new gold standard in predicting mortality in patients with advanced heart failure [J].
Gardner, RS ;
Özalp, F ;
Murday, AJ ;
Robb, SD ;
McDonagh, TA .
EUROPEAN HEART JOURNAL, 2003, 24 (19) :1735-1743
[4]   Increased cardiac BNP expression associated with myocardial ischemia [J].
Goetze, JP ;
Christoffersen, C ;
Perko, M ;
Arendrup, H ;
Rehfeld, JF ;
Kastrup, J ;
Nielsen, LB .
FASEB JOURNAL, 2003, 17 (06) :1105-+
[5]   Essential biochemistry and physiology of (NT-pro)BNP [J].
Hall, C .
EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (03) :257-260
[6]   RAPID VENTRICULAR INDUCTION OF BRAIN NATRIURETIC PEPTIDE GENE-EXPRESSION IN EXPERIMENTAL ACUTE MYOCARDIAL-INFARCTION [J].
HAMA, N ;
ITOH, H ;
SHIRAKAMI, G ;
NAKAGAWA, O ;
SUGA, S ;
OGAWA, Y ;
MASUDA, I ;
NAKANISHI, K ;
YOSHIMASA, T ;
HASHIMOTO, Y ;
YAMAGUCHI, M ;
HORI, R ;
YASUE, H ;
NAKAO, K .
CIRCULATION, 1995, 92 (06) :1558-1564
[7]   N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease [J].
Kragelund, C ;
Gronning, B ;
Kober, L ;
Hildebrandt, P ;
Steffensen, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (07) :666-675
[8]  
Levin ER, 1998, NEW ENGL J MED, V339, P321
[9]   Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic to severity, and left ventricular ejection fraction [J].
Ndrepepa, G ;
Braun, S ;
Mehilli, J ;
von Beckerath, N ;
Vogt, W ;
Schömig, A ;
Kastrati, A .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (05) :553-557
[10]   Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction - Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide [J].
Omland, T ;
Aakvaag, A ;
Bonarjee, VVS ;
Caidahl, K ;
Lie, RT ;
Nilsen, DWT ;
Sundsfjord, JA ;
Dickstein, K .
CIRCULATION, 1996, 93 (11) :1963-1969